CA
NZ
UK
AU
IND
US
…
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Arcus Biosciences (NYSE: RCUS) is a clinical-stage biopharmaceutical company developing cancer immunotherapies and targeted oncology treatments. Long-term growth drivers include positive clinical trial readouts, regulatory approvals, and strategic partnerships that could support commercialization if programs succeed. Investors may find exposure to novel immuno-oncology approaches and upside from trial or partnership milestones attractive.
Material risks include high clinical and regulatory failure probability, significant cash burn and potential dilution, and intense competition in immuno-oncology that may limit commercial prospects.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -353.00M | -283.00M | -301.00M | -266.00M | 54.65M |
| Net income | -353.00M | -283.00M | -307.00M | -267.00M | 52.83M |
| Selling general administrative | 110.00M | 120.00M | 117.00M | 104.00M | 72.29M |
| Selling and marketing expenses | - | - | 17.00M | - | - |
| Gross profit | 237.00M | 258.00M | 117.00M | 112.00M | 382.88M |
| Reconciled depreciation | 10.00M | 10.00M | 8.00M | 6.00M | 3.84M |
| Ebit | -345.00M | -279.00M | -299.00M | -280.00M | 54.25M |
| Ebitda | -335.00M | -269.00M | -291.00M | -264.00M | 54.91M |
| Depreciation and amortization | 10.00M | 10.00M | 8.00M | 16.00M | 0.66M |
| Non operating income net other | - | - | - | - | 0.40M |
| Operating income | -386.00M | -330.00M | -340.00M | -280.00M | 54.25M |
| Other operating expenses | 633.00M | 588.00M | 457.00M | 392.00M | 328.63M |
| Interest expense | 8.00M | 4.00M | 2.00M | 2.00M | 0.26M |
| Tax provision | 0.00M | 1.00M | 6.00M | 1.00M | 1.81M |
| Interest income | 41.00M | 52.00M | 41.00M | 16.00M | 0.66M |
| Net interest income | 33.00M | 48.00M | 39.00M | 14.00M | 0.40M |
| Income tax expense | - | 1.00M | 6.00M | 1.00M | 1.81M |
| Total revenue | 247.00M | 258.00M | 117.00M | 112.00M | 382.88M |
| Total operating expenses | 623.00M | 588.00M | 457.00M | 392.00M | 328.63M |
| Cost of revenue | 10.00M | 10.00M | 340.00M | - | - |
| Total other income expense net | 33.00M | 47.00M | 39.00M | 14.00M | 0.40M |
| Net income from continuing ops | -353.00M | -284.00M | -307.00M | -267.00M | 52.83M |
| Net income applicable to common shares | - | - | - | -267.00M | 52.83M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1139.00M | 1150.00M | 1095.00M | 1345.00M | 1591.90M |
| Other current assets | 10.00M | 13.00M | 30.00M | 58.00M | 15.62M |
| Total liab | 508.00M | 665.00M | 633.00M | 688.00M | 750.45M |
| Total stockholder equity | 631.00M | 485.00M | 462.00M | 657.00M | 841.45M |
| Deferred long term liab | - | - | - | 3.00M | 4.00M |
| Other current liab | 141.00M | 122.00M | 65.00M | 76.00M | 0.05M |
| Common stock | 2116.00M | 1617.00M | 1311.00M | 1206.00M | 0.01M |
| Capital stock | 2116.00M | 1617.00M | 1311.00M | 1206.00M | 0.01M |
| Retained earnings | -1485.00M | -1132.00M | -849.00M | -542.00M | -275.35M |
| Other liab | - | - | - | 378.00M | 467.48M |
| Other assets | - | - | - | 14.00M | 10.73M |
| Cash | 222.00M | 150.00M | 127.00M | 206.00M | 147.91M |
| Total current liabilities | 231.00M | 226.00M | 184.00M | 193.00M | 166.08M |
| Current deferred revenue | 35.00M | 85.00M | 91.00M | 97.00M | 102.00M |
| Net debt | -110.00M | -90.00M | -116.00M | -206.00M | -31.03M |
| Short term debt | 13.00M | 12.00M | 11.00M | - | 53.77M |
| Short long term debt total | 112.00M | 60.00M | 11.00M | - | 116.89M |
| Other stockholder equity | - | - | - | -7.00M | 1118.06M |
| Property plant equipment | - | - | - | 135.00M | 32.45M |
| Total current assets | 1007.00M | 1016.00M | 831.00M | 1067.00M | 681.30M |
| Long term investments | 29.00M | 14.00M | 107.00M | 129.00M | 181.99M |
| Net tangible assets | - | - | - | 657.00M | 841.45M |
| Short term investments | 759.00M | 828.00M | 632.00M | 803.00M | 351.39M |
| Net receivables | 16.00M | 25.00M | 42.00M | 43.00M | 746.82M |
| Long term debt | 99.00M | 48.00M | - | - | - |
| Inventory | - | - | - | -172.00M | -762.44M |
| Accounts payable | 42.00M | 18.00M | 17.00M | 20.00M | 10.26M |
| Accumulated other comprehensive income | - | - | - | -7.00M | -1.26M |
| Common stock total equity | - | - | - | - | 0.01M |
| Retained earnings total equity | - | - | - | - | -275.35M |
| Non currrent assets other | 63.00M | 73.00M | 106.00M | 114.00M | 591.19M |
| Non current assets total | 132.00M | 134.00M | 264.00M | 278.00M | 910.60M |
| Capital lease obligations | 13.00M | 12.00M | 11.00M | - | 116.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 68.00M | -84.00M | 213.00M | -413.00M | -28.79M |
| Change to liabilities | - | - | - | -104.00M | 4.87M |
| Total cashflows from investing activities | 66.00M | -84.00M | 194.00M | -413.00M | -3.87M |
| Net borrowings | 49.00M | 47.00M | 0.00M | - | - |
| Total cash from financing activities | 488.00M | 277.00M | 33.00M | 33.00M | 237.34M |
| Change to operating activities | - | - | - | 23.00M | 14.09M |
| Net income | -353.00M | -283.00M | -307.00M | -267.00M | 52.83M |
| Change in cash | 72.00M | 23.00M | -79.00M | 58.00M | -22.70M |
| Begin period cash flow | 153.00M | 130.00M | 209.00M | 151.00M | 173.62M |
| End period cash flow | 225.00M | 153.00M | 130.00M | 209.00M | 150.92M |
| Total cash from operating activities | -482.00M | -170.00M | -306.00M | 438.00M | -256.17M |
| Issuance of capital stock | 429.00M | 228.00M | 36.00M | 23.00M | 220.24M |
| Depreciation | 10.00M | 10.00M | 8.00M | 6.00M | 3.84M |
| Other cashflows from investing activities | - | - | - | 3.00M | 51.00M |
| Change to inventory | - | - | -15.00M | - | 14.09M |
| Change to account receivables | 9.00M | 28.00M | 15.00M | 704.00M | -17.05M |
| Sale purchase of stock | - | - | - | - | -0.01M |
| Other cashflows from financing activities | 488.00M | 2.00M | 8.00M | 10.00M | 17.11M |
| Change to netincome | - | - | - | 76.00M | 54.53M |
| Capital expenditures | 2.00M | 6.00M | 24.00M | 12.00M | 26.08M |
| Cash flows other operating | - | - | - | - | -377.01M |
| Cash and cash equivalents changes | - | - | - | - | -22.70M |
| Change in working capital | -194.00M | 22.00M | -71.00M | 623.00M | -375.62M |
| Stock based compensation | 60.00M | 76.00M | 73.00M | 65.00M | 54.53M |
| Other non cash items | -5.00M | 5.00M | -9.00M | 11.00M | 3.47M |
| Free cash flow | -484.00M | -176.00M | -330.00M | 426.00M | -282.25M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences Inc |
-0.42 2.26% |
18.19 | - | - | 26.14 | 6.61 | 21.17 | 3.96 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO | 1960 |
| Dr. Juan Carlos Jaen Ph.D. | Co-Founder, Pres & Director | 1958 |
| Mr. Robert C. Goeltz II | Principal Financial & Accounting Officer and CFO | 1973 |
| Ms. Jennifer A. Jarrett M.B.A. | COO & Director | 1971 |
| Ms. Carolyn C. Tang J.D. | Gen. Counsel & Corp. Sec. | 1979 |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board | NA |
| Dr. Stephen Young Ph.D. | Sr. VP of Technology & Quantitative Biology | 1969 |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer | 1969 |
| Ms. Katherine Bock | VP of Investor Relations & Corp. Strategy | NA |
| Holli Kolkey | VP of Corp. Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...